Penicillin changed the world. This drug could too. ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Micro Cap Watch.
Biotech company has a potentially revolutionary antiviral drug where viruses are unlikely to escape! We live in a world where viruses are getting stronger and deadlier. What if there was a way to fight these viruses the way antibiotics fight bacteria? One small-cap biotech company has a treatment that was found to have possibly completely cured the lethal RSV infection in mice! This was based on indefinite survival of the animals with no lung pathology. There is currently no treatment for RSV infection making it an opportunistic time to have your eyes on the company. In particular, pediatric RSV infection treatment is an unmet medical need that is of critical importance. Pediatric RSV treatment itself is expected to be a multi-billion-dollar market in the USA alone. And it doesn’t stop at just RSV. The company’s treatment could be used for COVID, the Flu, and other viruses. Why is this biotech company standing out? The company’s treatment solves the greatest problem in antiviral countermeasures; the problem of virus escape. Viruses are known to escape all the current antiviral tools that include vaccines, antibodies, and small chemical drugs. The company’s treatment of viral infections is reminiscent of how penicillin revolutionized the treatment of bacterial infections. It was even found to be substantially superior to three approved anti-influenza drugs, namely, oseltamivir (Tamiflu®, Roche), peramivir (Rapivab®, Biocryst), and baloxavir (Xofluza®, Shionogi/Roche)! With plenty of cash on hand, discover how this small-cap biotech firm is revolutionizing antiviral therapy and building shareholder value. Micro Cap Watch |
Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431 We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of NanoViricides, Inc. (NYSE American: NNVC). The compensation consists of up to $3,500 and was received/will be received from Interactive Offers. This compensation should not be considered as an endorsement of the securities of adviser NanoViricides, Inc. (NYSE American: NNVC) and we are not responsible for any errors or omissions in any information provided about the securities of NanoViricides, Inc. (NYSE American: NNVC) and Financial Markets Daily. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 12/18/24. Behind the Markets
Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices.
You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. |
|
Tidak ada komentar:
Posting Komentar